NCT01394939 - Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

October 31, 2015

Conditions

Colorectal CarcinomaCRC

Interventions

BIOLOGICAL

JX-594

Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

DRUG

Irinotecan

180 mg/m2 IV every 2 weeks.

Trial Locations (11)

Institut Claudius Regaud, Toulouse

The Ohio State University, Columbus

Gabrail Cancer Center, Canton

Billings Clinic Cancer Center, Billings

Hôpital Hautepierre, Strasbourg

Hôpital Saint Antoine, Paris

UCSD Moores Cancer Center, La Jolla

Mayo Clinic, Scottsdale

University of North Carolina, Chapel Hill

Juravinski Cancer Centre, Hamilton

Ottawa Hospital and Research Institute (OHRI), Ottawa